Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific.

@article{Golan2016ShiftingPI,
  title={Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific.},
  author={Daniel Golan and Elsebeth Staun-ram and Ariel Miller},
  journal={Current Opinion in Neurology},
  year={2016}
}
PURPOSE OF REVIEW In recent years we notice paradigm shifts in the understanding of multiple sclerosis (MS), leading to important transition in the patients' management. This review discusses some of the recent findings and developments underlying the conceptual changes being translated from 'treating the disease' to 'treating the patient' with MS (PwMS). RECENT FINDINGS Applying advanced technologies combined with cross-disciplinary efforts in the fields of neuropathology, neuroimmunology… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
11 Citations
Background Citations
1
Results Citations
1

11 Citations

Digital Twins for Multiple Sclerosis

The use of digital twins for MS is discussed as a revolutionary tool to improve diagnosis, monitoring and therapy refining patients’ well-being, saving economic costs, and enabling prevention of disease progression.

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

An overview of the role of IFN in the treatment of MS is provided and the available evidence for pegylated IFN therapy in MS is evaluated.

Multiple sclerosis: renaming the notorious and historical diagnosis?

The notorious ‘MS’ label should be updated, perhaps by removing the reference to high recurrence of the disease (‘multiple’) or replacing ‘sclerosis’, which is a noun that carries a morbid connotation.

Focus group on the experience of patients and family members in the multiple sclerosis unit of a tertiary hospital

GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients

The findings suggest the need to investigate GP6’s rs2304166 role as a potential pharmacogenetic predictor for MS patients’ response to natalizumab.

Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway

Current findings on the correlation between latitude, sunlight and vitamin D, and their effects on intestinal calcium absorption, gut microbiota and neuroinflammatory mediators in MS are summarized and a new mechanistic pathway for the initiation of MS is proposed.

The road ahead for health and lifespan interventions

Recognizing the need for personalization of haemophilia patient‐reported outcomes in the prophylaxis era

The underlying rationale for GAS and one other novel approach to PRO personalization are presented, and their potential to augment current outcome measures by reliably detecting and quantifying treatment effects in individuals with haemophilia on prophylaxis is discussed.

Promoting Collaborations Between Radiologists and Scientists.

SERUM LACTATE AS A BIOMARKER IN MULTIPLE SCLEROSIS

This dissertation aims to provide a history of neurology in Egypt from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which Mohamed El-Sheikh University was founded.

References

SHOWING 1-10 OF 91 REFERENCES

Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets

The goal of this review is to summarize how B-cells may contribute to MS pathogenesis and thereby provide a basis for understanding why B-cell depletion is so effective in the treatment of this disease.

Cerebrospinal fluid proteomics in multiple sclerosis.

Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?

The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors.

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

An overview of the role of IFN in the treatment of MS is provided and the available evidence for pegylated IFN therapy in MS is evaluated.

Peripheral blood biomarkers in multiple sclerosis.

Signaling networks in MS: A systems-based approach to developing new pharmacological therapies

Together, data suggest that MS is likely to be associated with abnormalities in apoptosis/cell death, microglia activation, blood-brain barrier functioning, immune responses, cytokine production, and/or oxidative stress, although which pathways contribute to the cascade of damage and can be modulated remains an open question.

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage, and results confirm increased neurofilament levels already in CIS being related to the level of physical disability.

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

Past prospects for developing targeted therapeutics aimed at reducing disability in progressive forms of MS appear promising, and various therapies under study in phase II or III trials are discussed.

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

CSF N-acetylaspartate levels were not different from patients without neurologic disease in early stages of multiple sclerosis, though decreased as the disease progressed, and combined with neurofilament levels yields information on different phases of axonal pathology.
...